Tissue Regenix Group yesterday announced the immediate appointment of Steve Couldwell as Chief Executive Officer (CEO).
“I am delighted to be appointed CEO and look forward to leading the Group through the integration of CellRight and expansion of commercial activities as we … grow our market share throughout the US and the rest of the world,” says Couldwell.
Couldwell has been a non-executive director of the board since 2013, and most recently was Chief Operating Officer (COO) of Global Sanofi Biosurgery. He has 25 years’ experience in the pharmaceutical and medical device industry, and has also held positions including president of Orthopaedics, Europe at Smith & Nephew.
“The board and I are delighted to welcome Steve as the Group’s new CEO. He has an exceptional track record of growing businesses and the board firmly believes that Steve has the required skillset and experience to guide the group along the pathway to profitability,” says John Samuel, chairman of Tissue Regenix. “Alongside this, Steve has an in-depth knowledge of the group thanks to his years as a non-executive director making him an ideal candidate for this position.”
“Since being appointed to the board in 2013 I have been impressed with the great commercial potential of our dCell platform,” adds Couldwell. “The recent acquisition of CellRight Technologies [in August 2017] has increased the market potential and provided a highly complementary product range in the US$1.7 billion (£1.3b) US bone graft and substitute market.”
Tissue Regenix’s flagship product is their dCell process, which produces an intact acellular matrix from biological tissues through a proprietary washing process. Tissue grafts made using the dCell process provide an “enhanced healing environment”, according to the company.
Tissue Regenix was founded at the University of Leeds, UK, in 2006 and now operates a subsidiary in the USA, Tissue Regenix Wound Care Inc. CellRight Technologies was acquired by the group in August 2017.